Vaccinia Virus, Live Modified

Summary

Vaccinia Virus, Live Modified (CHEMBL6068373) is an approved vaccine component; indicated across 3 conditions including monkeypox and smallpox.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 3 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068373
Name	Vaccinia Virus, Live Modified
Type	Vaccine component
Max phase	4

Also known as: Imvanex, Vaccinia virus, live modified, VACCINIA VIRUS, LIVE MODIFIED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
monkeypox	4	MONDO:0002594	MONDO:0002594
smallpox	4	MONDO:0004651	MONDO:0004651

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03953196	EARLY_PHASE1	COMPLETED	A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).